La Académie européenne d’allergologie et d’immunologie clinique (The European Academy of Allergy and Clinical Immunology, ...

Vistin Pharma ASA (VISTN) today announces the financial results for the second quarter of 2025. Revenue in the second quarter ended at MNOK 118 compared to MNOK 106 in Q2 2024. The increase in revenue ...

The information contained herein is such as shall be made public by Aino Health AB (publ), in accordance with the EU Market Abuse Regulation. This information was made public, through the agency of ...

Propanc Biopharma, Inc. (the “Company”) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells ...

Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study ; Cash balance of $48.5 million as of June 30, 2025 anticipated to fund key milestones through mid- ...

RxSight’s management is scheduled to present on Thursday, September 4, 2025, at 7:15 a.m. Pacific Time / 10:15 a.m. Eastern Time. A live and archived webcast of the presentation will be available at: ...

The Company intends to use the net proceeds from the initial public offering for furthering the development of its intranasal Epinephrine program, including, manufacturing scale-up and additional ...

BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for ...

NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...

On June 12, 2025, the Company was honored with the prestigious 2025 "Disinfection and Decontamination Products Company of the Year" award by MedTech Outlook. This recognition highlights TOMI’s ...

Submitting the Company’s Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration in the fourth quarter of 2025, to initiate a U.S. long-term, multicenter Pilot Study of the ...

Second quarter 2025 revenue was $3.3 million, a 17% increase over the second quarter of 2024. New accounts grew 75% in the second quarter of 2025 over the comparable quarter in 2024. CapsoCam Plus® ...